Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) revealed in a recent 8-K filing to the Securities and Exchange Commission that its proprietary Antibody Drug Conjugate (ADC) platform is now open for potential drug discovery partnerships. The filing, dated February 19, 2025, highlighted the Company’s strategy to advance the development of its ADC platform and the potential for creating multiple pipeline drug candidates through such collaborations.

Sonnet’s ADC platform is designed to address technical challenges commonly associated with ADCs. Leveraging the proven targeting of the F H AB domain, the platform offers flexible payload capacity and controllable drug-antibody ratios. In a preclinical study, an epidermal growth factor receptor 2 (HER2) ADC construct known as SON-5010 exhibited similar activities to established products like Kadcyla® and trastuzumab-MMAE.

The company emphasized that its ADC platform provides the potential for novel ADCs with distinct structural integrity, tumor targeting capabilities, interchangeability of toxin payloads, and flexible conjugation sites usage. The initial proof-of-concept construct, SON-5010, demonstrates promising features and has been compared with approved products like Kadcyla®.

Sonnet’s management expressed optimism about the early success of the SON-5010 ADC construct and the platform’s potential for diverse applications in cancer therapy. Dr. Stephen McAndrew, Chief Business Officer at Sonnet, highlighted the platform’s distinguishing features, including flexibility in targeting scaffolds, controlled DARs, and a range of payload choices.

The Company’s commitment to advancing drug development and seeking strategic partnerships was a focal point in the filing. Sonnet continues to innovate in the oncology space, with its lead program SON-1010 in development for various tumor types. Additionally, Sonnet’s programs like SON-080 for peripheral neuropathy have shown promising results, positioning the company for further clinical advancements.

Investors were reminded that forward-looking statements in the filing are subject to risks and uncertainties, cautioning against undue reliance on such statements. Sonnet BioTherapeutics is dedicated to maintaining transparency and providing updates on its progress as it moves forward with its innovative ADC platform and drug development endeavors.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sonnet BioTherapeutics’s 8K filing here.

Sonnet BioTherapeutics Company Profile

Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.